# Gemini Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gemini-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.geminitherapeutics.com
- Total disclosed funding: $45M
- Latest round: Series A (Oct 17, 2017)
- Investors on record: 3

## About

Gemini Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious eye diseases, utilizing advanced gene therapy techniques for targeted treatments.Founded in 2015, Gemini Therapeutics, Inc. operates out of Cambridge, US, specializing in therapies for eye diseases. The company recently underwent a merger with FS Development Corp. in a deal that enabled it to further enhance its clinical and preclinical portfolio. Jason Meyenburg serves as the CEO, leading the firm after its merger, which involved considerable investments from various esteemed investment groups, including Foresite Capital and Acorn Bioventures. The company has executed a total of 3 deals, with the most recent transaction occurring on February 5, 2021, resulting in a total raised amount of USD 42.50 mn, including USD 95 mn from the PIPE deal.Gemini Therapeutics, Inc. develops gene therapies aimed at treating debilitating eye diseases. The company’s primary focus is on innovative treatment options that leverage genetic engineering to address specific conditions affecting vision and eye health. Through its clinical programs, Gemini aims to provide solutions that significantly improve patients' quality of life by restoring vision.Gemini Therapeutics, Inc. generates revenue primarily through funding for its clinical programs and partnerships with other biotech firms and investors involved in its research initiatives. The company’s financial structure includes investment from strategic partners, which supports its innovative therapeutic development and research activities.Following its merger on February 5, 2021, Gemini Therapeutics, Inc. is set to utilize the USD 95 mn raised during the transaction to bolster its clinical programs and expand its preclinical portfolio. The company aims to launch new gene therapy products targeting various ocular conditions in the next few years, enhancing its presence in the biotechnology market. Additionally, Gemini is exploring opportunities for geographic expansion into international markets, with plans to establish a foothold in Europe and Asia by 2024, capitalizing on the global demand for innovative eye treatments.

## Funding rounds

- Series A, Oct 17, 2017, $43M — Atlas Venture, OrbiMed Advisors, Lightstone Ventures
- Seed, Apr 19, 2016, $2M — Atlas Venture, OrbiMed Advisors, Lightstone Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed, Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Seed, Series A